Literature DB >> 19584719

Molecular markers of aggressiveness of thyroid cancer.

Matthew D Ringel1.   

Abstract

PURPOSE OF REVIEW: To review recent progress at defining molecular markers that predict the biological behavior of thyroid cancer. RECENT
FINDINGS: Thyroid cancer behavior is defined by the effects of the initiating oncogene as well as secondary events in tumor cells and the tumor microenvironment that are both genetic and epigenetic. Over the past several years, there has been intense focus on identifying molecular markers to better predict the aggressiveness of thyroid cancers and also to define therapeutic targets. The results of recent articles in this area of work are summarized with a focus of differentiated follicular-cell-derived forms of thyroid cancer.
SUMMARY: Clinical staging predicts tumor behavior in many cases, but does not allow true 'personalization' of initial therapy or identify potential therapeutic targets for patients with progressive disease that does not respond to standard therapies. Recent data point to several new opportunities to refine thyroid cancer treatment based on molecular information. Several highlighted articles have begun to apply this information with clinical intent.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584719      PMCID: PMC2873681          DOI: 10.1097/MED.0b013e32832ff2cb

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  60 in total

1.  The role of microRNA genes in papillary thyroid carcinoma.

Authors:  Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

2.  Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.

Authors:  Thomas J Giordano; Rork Kuick; Dafydd G Thomas; David E Misek; Michelle Vinco; Donita Sanders; Zhaowen Zhu; Raffaele Ciampi; Michael Roh; Kerby Shedden; Paul Gauger; Gerard Doherty; Norman W Thompson; Samir Hanash; Ronald J Koenig; Yuri E Nikiforov
Journal:  Oncogene       Date:  2005-10-06       Impact factor: 9.867

3.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.

Authors:  D Liaw; D J Marsh; J Li; P L Dahia; S I Wang; Z Zheng; S Bose; K M Call; H C Tsou; M Peacocke; C Eng; R Parsons
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

4.  Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.

Authors:  Guojun Wu; Elizabeth Mambo; Zhongmin Guo; Shuiying Hu; Xin Huang; Susanne M Gollin; Barry Trink; Paul W Ladenson; David Sidransky; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2005-05-31       Impact factor: 5.958

5.  Mutation of the PIK3CA gene in anaplastic thyroid cancer.

Authors:  Ginesa García-Rostán; Angela M Costa; Isabel Pereira-Castro; Giuliana Salvatore; Radhames Hernandez; Mario J A Hermsem; Agustin Herrero; Alfredo Fusco; Jose Cameselle-Teijeiro; Massimo Santoro
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

6.  Overexpression and overactivation of Akt in thyroid carcinoma.

Authors:  M D Ringel; N Hayre; J Saito; B Saunier; F Schuppert; H Burch; V Bernet; K D Burman; L D Kohn; M Saji
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

7.  RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors.

Authors:  Nobuki Nakamura; J Aidan Carney; Long Jin; Sabine Kajita; Judit Pallares; Heyu Zhang; Xiang Qian; Thomas J Sebo; Lori A Erickson; Ricardo V Lloyd
Journal:  Lab Invest       Date:  2005-09       Impact factor: 5.662

8.  Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker.

Authors:  Volkert B Wreesmann; Elizabeth M Sieczka; Nicholas D Socci; Michael Hezel; Thomas J Belbin; Geoffrey Childs; Snehal G Patel; Kepal N Patel; Giovanni Tallini; Michael Prystowsky; Ashok R Shaha; Dennis Kraus; Jatin P Shah; Pulivarthi H Rao; Ronald Ghossein; Bhuvanesh Singh
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

9.  Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis.

Authors:  Mingzhao Xing; Yoram Cohen; Elizabeth Mambo; Giovanni Tallini; Robert Udelsman; Paul W Ladenson; David Sidransky
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

10.  BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

Authors:  Mingzhao Xing; Douglas Clark; Haixia Guan; Meiju Ji; Alan Dackiw; Kathryn A Carson; Matthew Kim; Anthony Tufaro; Paul Ladenson; Martha Zeiger; Ralph Tufano
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

View more
  10 in total

1.  Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.

Authors:  Samantha K McCarty; Motoyasu Saji; Xiaoli Zhang; David Jarjoura; Alfredo Fusco; Vasyl V Vasko; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2010-10-29       Impact factor: 5.678

Review 2.  Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier.

Authors:  Matthew D Ringel
Journal:  Thyroid       Date:  2011-04-10       Impact factor: 6.568

3.  BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.

Authors:  S Fraser; C Go; A Aniss; S Sidhu; L Delbridge; D Learoyd; R Clifton-Bligh; L Tacon; V Tsang; B Robinson; A J Gill; M Sywak
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

4.  BRAF activates and physically interacts with PAK to regulate cell motility.

Authors:  Samantha K McCarty; Motoyasu Saji; Xiaoli Zhang; Christina M Knippler; Lawrence S Kirschner; Soledad Fernandez; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2014-09-16       Impact factor: 5.678

5.  Molecular Heterogeneity of Papillary Thyroid Cancer: Comparison of Primary Tumors and Synchronous Metastases in Regional Lymph Nodes by Mass Spectrometry Imaging.

Authors:  Marta Gawin; Agata Kurczyk; Ewa Stobiecka; Katarzyna Frątczak; Joanna Polańska; Monika Pietrowska; Piotr Widłak
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

Review 6.  Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?

Authors:  Dagmara Rusinek; Ewa Chmielik; Jolanta Krajewska; Michal Jarzab; Malgorzata Oczko-Wojciechowska; Agnieszka Czarniecka; Barbara Jarzab
Journal:  Int J Mol Sci       Date:  2017-08-22       Impact factor: 5.923

7.  PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome.

Authors:  Martina Sollini; Luca di Tommaso; Margarita Kirienko; Chiara Piombo; Marco Erreni; Andrea Gerardo Lania; Paola Anna Erba; Lidija Antunovic; Arturo Chiti
Journal:  EJNMMI Res       Date:  2019-10-15       Impact factor: 3.138

Review 8.  New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking.

Authors:  Mourad Zerfaoui; Titilope Modupe Dokunmu; Eman Ali Toraih; Bashir M Rezk; Zakaria Y Abd Elmageed; Emad Kandil
Journal:  Cells       Date:  2021-02-10       Impact factor: 6.600

9.  Extensive lymphatic spread of papillary thyroid microcarcinoma is associated with an increase in expression of genes involved in epithelial-mesenchymal transition and cancer stem cell-like properties.

Authors:  Sohee Lee; Ja Seong Bae; Chan Kwon Jung; Woong Youn Chung
Journal:  Cancer Med       Date:  2019-09-09       Impact factor: 4.452

10.  Extracellular Vesicles as Signal Carriers in Malignant Thyroid Tumors?

Authors:  Małgorzata Grzanka; Anna Stachurska-Skrodzka; Anna Adamiok-Ostrowska; Ewa Gajda; Barbara Czarnocka
Journal:  Int J Mol Sci       Date:  2022-03-17       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.